WASHINGTON, D.C. — The Federal Trade Commission alleges Martin Shkreli, the former pharmaceutical executive, publicly demonstrated his evasion of a lifetime ban from the drug industry during a recent online livestream. The agency says his actions constitute a continuing violation of court orders.

Shkreli, who famously raised the price of a life-saving anti-parasitic drug to nearly $1,000 a pill in 2015, was ordered by a federal judge in 2016 to refrain from owning or operating a pharmaceutical company. Despite this restriction, he has maintained a significant presence in the biotech sector through stock trading and public commentary.

“I can always find a couple of biotech stocks to smoke,” Shkreli said during a livestream session where he discussed his investment portfolio. The FTC contends that these statements and subsequent actions represent a blatant disregard for the injunction, suggesting a pattern of willful non-compliance rather than accidental oversight by the former founder of Phathom BioSciences.

Key Takeaways

• The FTC has formally accused Shkreli of violating a 2016 lifetime ban on pharmaceutical business operations.
• Public livestreams have become a primary channel for Shkreli to discuss drug prices and biotech investments.
• Enforcement actions may result in significant civil penalties, although Shkreli’s current liquid assets remain limited.

Agency investigators reviewed social media archives and financial disclosures to build their case. The FTC, under new leadership, has expressed a renewed commitment to policing market manipulators who exploit gaps between legacy regulations and modern digital communication. The ban was originally imposed to protect consumers from predatory pricing practices that have historically harmed patients with chronic conditions.

Clinical impact remains a central concern for health policy analysts. Shkreli’s involvement in drug markets, even indirectly through stock speculation, fuels public distrust in pharmaceutical pricing. Patients with rare diseases, who are often left without affordable options, cite his legacy as a primary driver of rising healthcare costs across the United States over the last decade.

Shkreli’s representatives have not yet issued a formal response to the FTC’s allegations. Legal experts note that while the ban prohibits direct operational control, it does not strictly preclude holding passive investments in publicly traded biotechnology firms. However, the FTC argues that his active engagement and public commentary cross the line into prohibited business activity.

The commission is expected to file a motion for contempt in federal court, seeking to enforce the original terms of the settlement. If successful, the ruling could establish a legal precedent for how digital speech and passive investment are interpreted under industry exclusion orders in the modern era.

This enforcement action underscores the increasing tension between legacy regulatory frameworks and the digital economy. As pharmaceutical companies continue to list on public exchanges, defining the boundaries of prohibited conduct becomes a complex legal challenge for federal agencies tasked with protecting public health.